- Home
- TRVI vs SABA Comparison
TRVI vs SABA Comparison
Compare TRVI & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- SABA
- Stock Information
- Founded
- TRVI 2011
- SABA 1988
- Country
- TRVI United States
- SABA United States
- Employees
- TRVI N/A
- SABA N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- TRVI Health Care
- SABA
- Exchange
- TRVI Nasdaq
- SABA Nasdaq
- Market Cap
- TRVI 211.4M
- SABA 245.3M
- IPO Year
- TRVI 2019
- SABA N/A
- Fundamental
- Price
- TRVI $2.75
- SABA $8.61
- Analyst Decision
- TRVI Strong Buy
- SABA
- Analyst Count
- TRVI 8
- SABA 0
- Target Price
- TRVI $9.13
- SABA N/A
- AVG Volume (30 Days)
- TRVI 659.5K
- SABA 290.0K
- Earning Date
- TRVI 11-06-2024
- SABA 01-01-0001
- Dividend Yield
- TRVI N/A
- SABA 12.91%
- EPS Growth
- TRVI N/A
- SABA N/A
- EPS
- TRVI N/A
- SABA N/A
- Revenue
- TRVI N/A
- SABA N/A
- Revenue This Year
- TRVI N/A
- SABA N/A
- Revenue Next Year
- TRVI N/A
- SABA N/A
- P/E Ratio
- TRVI N/A
- SABA N/A
- Revenue Growth
- TRVI N/A
- SABA N/A
- 52 Week Low
- TRVI $0.97
- SABA $3.64
- 52 Week High
- TRVI $4.00
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- TRVI 37.52
- SABA 53.06
- Support Level
- TRVI $2.80
- SABA $8.51
- Resistance Level
- TRVI $3.22
- SABA $8.64
- Average True Range (ATR)
- TRVI 0.20
- SABA 0.10
- MACD
- TRVI -0.03
- SABA 0.00
- Stochastic Oscillator
- TRVI 14.68
- SABA 53.33
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Templeton Global Income Fund is a closed-end fund. It seeks high current income, with a secondary goal of capital appreciation. Under normal market conditions. The Fund invests at least over 80% of its net assets in income-producing securities, including debt securities of the United States and foreign issuers, including emerging markets.